ClinicalTrials.gg
Active, not recruitingNCT03186898Updated Nov 3, 2026Results posted

Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer

A Phase 3 interventional study of Proton Therapy and Photon Therapy in Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7 and Unresectable Hepatocellular Carcinoma, sponsored by NRG Oncology. Active, not recruiting at 27 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by NRG Oncology · Phase 3, Interventional, and Treatment

How we know

Updated Nov 3, 2026Results postedStudy documents posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 926 studies in Carcinoma, Hepatocellular with a site in United States — 160 open to participants now, 245 under way, 17 of them phase 3. Carcinoma, Hepatocellular · United States.

Enrollment
169th of 775
116 · median 36
Started
2018
with 48 others
Phase 3
61 of 926
4 open now
Primary completion
2026-01
later than 41 of 244 live
Registered
502nd of 926
by date

Among the 926 studies in Carcinoma, Hepatocellular with a site in United States, this one is the 169th largest by enrollment of the 775 interventional ones that give a count, is one of 49 that started in 2018, is one of 61 in phase 3, reaches primary completion later than 41 of the 244 other live ones, and was the 502nd registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

160 of the 926 studies in Carcinoma, Hepatocellular with a site in United States are open now. Recruiting first, the newest first:

155 more — sign in →

All 160 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 926 studies in Carcinoma, Hepatocellular with a site in United States, or all of them as a file.
02

Study summary

This phase III trial studies how well radiation therapy with protons works compared with photons in treating patients with liver cancer. Radiation therapy, such as photon therapy, uses high energy x-rays to send the radiation inside the body to the tumor while proton therapy uses a beam of proton particles. Proton therapy can stop shortly after penetrating through the tumor and may cause less damage to the surrounding healthy organs and result in better survival in patients with liver cancer.

Read the detailed description

PRIMARY OBJECTIVE:

I. To determine if overall survival (OS) is different for hepatocellular carcinoma patients treated with protons compared to photons.

SECONDARY OBJECTIVES:

I. To determine the difference in progression-free-survival (PFS) in patients with hepatocellular carcinoma (HCC) treated with protons compared to patients with HCC treated with photons.

II. To determine the difference in local progression (LP) in patients with HCC treated with protons compared to patients with HCC treated with photons.

III. To determine differences in toxicity in patients with HCC treated with protons versus photons.

IV. To determine differences in fatigue, as measured by Patient-Reported Outcomes Measurement Information System (PROMIS) fatigue in patients with HCC treated with protons, versus photons; as well as quality-adjusted survival, if the primary endpoint is met.

V. To determine if there are correlations between the baseline values of hepatocyte growth factor (HGF) and outcomes (OS/PFS/fatigue).

EXPLORATORY OBJECTIVES:

I. To determine differences in overall quality of life, measured by Functional Assessment of Cancer Therapy-Hepatobiliary Cancer (FACT-Hep) in patients with HCC treated with protons.

II. Biospecimen collection for future correlative science projects.

OUTLINE: Patients are randomized to 1 of 2 arms, photon or proton therapy (see Arms and Interventions).

Patients undergo computed tomography (CT) scan, magnetic resonance imaging (MRI) and blood sample collection throughout the study.

After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 3 years, and then yearly thereafter.

03

Conditions studied

  • Recurrent Hepatocellular Carcinoma
  • Stage III Hepatocellular Carcinoma AJCC v7
  • Unresectable Hepatocellular Carcinoma
04

Who can participate

The criteria were revised on the registry on Nov 3, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pathologically (histologically or cytologically) or radiographically-proven (based on the American Association for the Study of Liver Diseases [AALSD] criteria) unresectable or locally recurrent hepatocellular cancer prior to registration
  • Appropriate stage for study entry based on the following diagnostic workup:

    • All patients must have computed tomography (CT) scan chest/abdomen/pelvis with multiphasic liver CT scan prior to registration; if CT contrast is , CT chest without contrast and magnetic resonance imaging (MRI) of abdomen is permitted
    • Participants must have at study entry, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 2 cm with conventional techniques or as > 1 cm with spiral CT scan
    • Patient must have 3 or fewer single or multinodular tumors; for patients with a single lesion, lesion must be 15 cm or less in greatest dimension; for patients with two lesions, no lesion may be greater than 10 cm in greatest dimension; for patients with three lesions, no lesion may be greater than 6 cm in greatest dimension; portal vein involvement or thrombosis combined with a single lesion that is >= 1 cm and =\< 15 cm in greatest dimension is allowed
  • Age >= 18
  • Zubrod performance status 0-1 within 30 days prior to registration
  • Negative urine or serum pregnancy test for women of within 7 days prior to study entry
  • (ANC) >= 1,000 cells/mm\^3
  • >= 50,000 cells/mm\^3
  • >= 9.0 g/dl; (Note: The use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 9.0 g/dl is acceptable)
  • Total \< 4 x institutional (ULN)
  • Transaminases ( [AST] and alanine aminotransferase [ALT]) \< 6 x institutional ULN
  • Albumin >= 2.5 g/dl
  • Creatinine \< 2 mg/dl
  • Prior chemotherapy, targeted biological therapy (e.g. sorafenib), surgery, transarterial chemoembolization (TACE), ablation for present disease is acceptable
  • Must have Child-Turcotte-Pugh (CTP) A or B7
  • The patient or a legally authorized representative must provide study-specific prior to study registration

Exclusion criteria

Exclusion Criteria:

  • PRIOR TO STEP ONE REGISTRATION:
  • Definitive clinical or radiologic documentation of extrahepatic tumor, defined as extrahepatic or malignant nodes (that enhance with typical features of HCC) > 3.0 cm, in sum of maximal diameters (e.g. presence of one 3.4 cm metastatic lymph node or two 2 cm lung lesions); note that benign non-enhancing periportal lymphadenopathy is not unusual in the presence of hepatitis and is permitted, even if the sum of enlarged nodes is > 2.0 cm
  • Uncontrolled prior invasive , excluding the current diagnosis
  • Systemic chemotherapy for the study cancer \< 2 weeks prior to registration
  • Pregnancy or women of and men who are sexually active and not willing/able to use medically acceptable forms of ; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic
  • positive with \< 200 cells/microliter; note that patients who are human immunodeficiency virus (HIV) positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 (cluster of differentiation 4)count >= 200 cells/microliter prior to registration; note also that HIV testing is not required for eligibility for this protocol; this exclusion criterion is necessary because the treatments involved in this protocol may be significantly
  • Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields (to include Y90)
  • Prior liver transplant
  • PRIOR TO STEP TWO RANDOMIZATION:
  • Unable to obtain confirmation of payment coverage (insurance or other) for either possible treatment
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
116 participants (actual)

Study arms

  • Experimental
    Proton Therapy (Arm 1)

    Proton therapy delivered in 5 fractions over 15 days or 15 fractions over 24 days, determined by the treating physician.

    Radiation: Proton Therapy

  • Experimental
    Photon Therapy (Arm 2)

    Photon therapy delivered in 5 fractions over 15 days or 15 fractions over 24 days, determined by the treating physician.

    Radiation: Photon Therapy

Interventions

  • RadiationProton Therapy

    Fractions

    Also known as: Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation

  • RadiationPhoton Therapy

    Fractions

    Also known as: Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Alive (Overall Survival)

    Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at last known follow-up.

    Time frame: From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months. One- and two-year estimates are reported.

Secondary outcomes

  1. Percentage of Participants Alive Without Progression (Progression-free Survival)

    Progression is defined as local, regional, or distant progression. Progression-free survival rates are estimated using the Kaplan-Meier method, censoring participants alive without progression at time of last follow-up.

    Time frame: From randomization to progression, death, or last follow-up, whichever occurs first. Median follow-up time for all patients at time of analysis was 20.4 months. One- and two-year estimates are reported.

  2. Percentage of Participants With Local Progression

    Local progression rates are estimated using the cumulative incidence method in which death is treated as competing risk and participants alive without local failure are censored at last known follow-up.

    Time frame: From randomization to local progression, death, or last follow-up, whichever occurs first. Median follow-up time for all patients at time of analysis was 20.4 months. One- and two-year estimates are reported.

  3. Percentage of Participants With Grade 3+ Treatment-Related Adverse Events

    Common Terminology Criteria for Adverse Events (version 5.0) grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. Adverse events reported as possibly, probably, or definitely related to treatment are considered to be treatment-related adverse events.

    Time frame: From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months.

  4. Change From Baseline to One Month in the Patient Reported Outcomes Measurement Information System - Fatigue Short Form version1.0 8a [PROMIS Fatigue Score]

    The PROMIS Fatigue Short Form v1.0 8a contains 8 items that assess self-reported fatigue symptoms over the past 7 days. Item responses are summed to obtain a raw score ranging from 8 to 40, which is then converted to a standardized T-score (mean = 50, standard deviation = 10). Higher T-scores indicate greater fatigue. Change from baseline is calculated as the post-baseline T-score minus the baseline T-score, with positive change scores indicating increased fatigue and negative change scores indicating decreased fatigue.

    Time frame: Baseline and one month

  5. Quality-adjusted LIfe Years

    Was to be calculated using the EuroQol 5-Dimension Three Level Questionnaire (EQ-5D-3L).

    Time frame: Baseline up to 12 months

  6. Percentage of Participants Alive (Overall Survival) by Plasma Hepatocyte Growth Factor (HGF) Level

    Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at last known follow-up. HGF will be dichotomized at 2311 pg/mL.

    Time frame: From randomization to death or last follow-up. One- and two-year estimates will be reported.

  7. Percentage of Participants Alive Without Progression (Progression-free Survival) by HGF Level

    Progression is defined as local, regional, or distant progression. Progression-free survival rates are estimated using the Kaplan-Meier method, censoring participants alive without progression at time of last follow-up. HGF will be dichotomized at 2311 pg/mL.

    Time frame: From randomization to progression, death, or last follow-up, whichever occurs first. One- and two-year estimates will be reported.

  8. Change From Baseline to One Month in PROMIS Fatigue Score by HGF Level

    The PROMIS Fatigue Short Form v1.0 8a contains 8 items that assess self-reported fatigue symptoms over the past 7 days. Item responses are summed to obtain a raw score ranging from 8 to 40, which is then converted to a standardized T-score (mean = 50, standard deviation = 10). Higher T-scores indicate greater fatigue. Change from baseline is calculated as the post-baseline T-score minus the baseline T-score, with positive change scores indicating increased fatigue and negative change scores indicating decreased fatigue. HGF will be dichotomized at 2311 pg/mL.

    Time frame: Baseline and one month

Other outcomes

  1. Overall Quality of Life by Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) Version 4

    Differences between treatment arms in the overall score, the four domains (physical, social, emotional, and functional well-being), and the additional concerns subscale will also be analyzed.

    Time frame: Baseline up to 12 months

  2. Title: Percentage of Participants Alive (Overall Survival) by Sex

    NIH-required analysis. Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at time of analysis.

    Time frame: From randomization to death or last follow-up. Median follow-up for all patients at time of analysis was 20.4 months. Two-year estimates are reported.

  3. Percentage of Participants Alive (Overall Survival) by Race

    NIH-required analysis. Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at time of analysis.

    Time frame: From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months. Two-year estimates are reported.

  4. Percentage of Participants Alive (Overall Survival) by Ethnicity

    NIH-required analysis. Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at time of analysis.

    Time frame: From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months. Two-year estimates are reported.

07

Results

Posted Nov 3, 2026
Limitations and caveats
The data monitoring committee (DMC) recommended early reporting of the trial when the interim analysis futility boundary was crossed

Participant flow

Participant flow — Overall Study
MilestoneProton Therapy (Arm 1)Photon Therapy (Arm 2)
Started5858
Primary analysis population5758
Safety population5355
Completed5758
Not completed10

Outcome measures

PrimaryPercentage of Participants Alive (Overall Survival)

Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at last known follow-up.

Time frame:
From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months. One- and two-year estimates are reported.
Reported as:
Number · Percentage of participants
Percentage of Participants Alive (Overall Survival)
Percentage of participantsProton Therapy (Arm 1)Photon Therapy (Arm 2)
One year77.0 (66.9 to 87.1)90.2 (83.3 to 97.1)
Two years56.2 (43.9 to 68.4)69.3 (57.3 to 81.2)
Statistical analysis
  • Proton Therapy (Arm 1) vs Photon Therapy (Arm 2) · Log Rank · p = 0.83 (One-side significance level = 0.05.) · Hazard ratio (hr): 1.30 · 90% CI 0.83 to 2.04Reference arm = Photon Therapy
SecondaryPercentage of Participants Alive Without Progression (Progression-free Survival)

Progression is defined as local, regional, or distant progression. Progression-free survival rates are estimated using the Kaplan-Meier method, censoring participants alive without progression at time of last follow-up.

Time frame:
From randomization to progression, death, or last follow-up, whichever occurs first. Median follow-up time for all patients at time of analysis was 20.4 months. One- and two-year estimates are reported.
Reported as:
Number · Percentage of participants
Percentage of Participants Alive Without Progression (Progression-free Survival)
Percentage of participantsProton Therapy (Arm 1)Photon Therapy (Arm 2)
One year55.5 (41.4 to 69.6)50.0 (35.6 to 64.4)
Two years31.6 (17.8 to 45.4)30.4 (15.9 to 44.8)
Statistical analysis
  • Proton Therapy (Arm 1) vs Photon Therapy (Arm 2) · Log Rank · p = 0.92 (Two-sided significance level = 0.05) · Hazard ratio (hr): 1.02 · 95% CI 0.65 to 1.62Reference arm = Photon Therapy
SecondaryPercentage of Participants With Local Progression

Local progression rates are estimated using the cumulative incidence method in which death is treated as competing risk and participants alive without local failure are censored at last known follow-up.

Time frame:
From randomization to local progression, death, or last follow-up, whichever occurs first. Median follow-up time for all patients at time of analysis was 20.4 months. One- and two-year estimates are reported.
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Progression
Percentage of participantsProton Therapy (Arm 1)Photon Therapy (Arm 2)
One year10.5 (3.8 to 21.2)15.1 (6.5 to 26.9)
Two years19.8 (9.6 to 32.7)22.3 (11.3 to 35.5)
Statistical analysis
  • Proton Therapy (Arm 1) vs Photon Therapy (Arm 2) · Gray's Test · p = 0.54 (Two-sided significance level = 0.05) · Hazard ratio (hr): 0.80 · 95% CI 0.36 to 1.77Reference arm = Photon Therapy
SecondaryPercentage of Participants With Grade 3+ Treatment-Related Adverse Events

Common Terminology Criteria for Adverse Events (version 5.0) grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. Adverse events reported as possibly, probably, or definitely related to treatment are considered to be treatment-related adverse events.

Time frame:
From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months.
Reported as:
Number · Percentage of participants
Percentage of Participants With Grade 3+ Treatment-Related Adverse Events
Percentage of participantsProton Therapy (Arm 1)Photon Therapy (Arm 2)
Percentage of Participants With Grade 3+ Treatment-Related Adverse Events11.3 (4.3 to 23.0)23.6 (13.2 to 37.0)
Statistical analysis
  • Proton Therapy (Arm 1) vs Photon Therapy (Arm 2) · Chi-squared · p = 0.093 (Two-sided significance level = 0.05)
SecondaryChange From Baseline to One Month in the Patient Reported Outcomes Measurement Information System - Fatigue Short Form version1.0 8a [PROMIS Fatigue Score]

The PROMIS Fatigue Short Form v1.0 8a contains 8 items that assess self-reported fatigue symptoms over the past 7 days. Item responses are summed to obtain a raw score ranging from 8 to 40, which is then converted to a standardized T-score (mean = 50, standard deviation = 10). Higher T-scores indicate greater fatigue. Change from baseline is calculated as the post-baseline T-score minus the baseline T-score, with positive change scores indicating increased fatigue and negative change scores indicating decreased fatigue.

Time frame:
Baseline and one month

Results for this outcome have not been posted.

SecondaryQuality-adjusted LIfe Years

Was to be calculated using the EuroQol 5-Dimension Three Level Questionnaire (EQ-5D-3L).

Time frame:
Baseline up to 12 months

No measurements were reported for this outcome.

SecondaryPercentage of Participants Alive (Overall Survival) by Plasma Hepatocyte Growth Factor (HGF) Level

Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at last known follow-up. HGF will be dichotomized at 2311 pg/mL.

Time frame:
From randomization to death or last follow-up. One- and two-year estimates will be reported.

Results for this outcome have not been posted.

Other pre-specifiedOverall Quality of Life by Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) Version 4

Differences between treatment arms in the overall score, the four domains (physical, social, emotional, and functional well-being), and the additional concerns subscale will also be analyzed.

Time frame:
Baseline up to 12 months

Results for this outcome have not been posted.

Other pre-specifiedTitle: Percentage of Participants Alive (Overall Survival) by Sex

NIH-required analysis. Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at time of analysis.

Time frame:
From randomization to death or last follow-up. Median follow-up for all patients at time of analysis was 20.4 months. Two-year estimates are reported.
Reported as:
Number · Percentage of participants
Title: Percentage of Participants Alive (Overall Survival) by Sex
Percentage of participantsProton Therapy (Arm 1)Photon Therapy (Arm 2)
Female66.1 (43.2 to 89.0)56.3 (29.1 to 83.4)
Male52.8 (38.5 to 67.1)73.1 (60.1 to 86.1)
Other pre-specifiedPercentage of Participants Alive (Overall Survival) by Race

NIH-required analysis. Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at time of analysis.

Time frame:
From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months. Two-year estimates are reported.
Reported as:
Number · Percentage of participants
Percentage of Participants Alive (Overall Survival) by Race
Percentage of participantsProton Therapy (Arm 1)Photon Therapy (Arm 2)
AsianNA (NA to NA)100 (NA to NA)
Black or African American100 (NA to NA)50 (8.9 to 91.1)
White53.2 (40.5 to 65.9)73.7 (61.0 to 86.3)
More than one raceNA (NA to NA)—
Unknown or Not Reported100 (NA to NA)41.7 (0.0 to 91.7)
Other pre-specifiedPercentage of Participants Alive (Overall Survival) by Ethnicity

NIH-required analysis. Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at time of analysis.

Time frame:
From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months. Two-year estimates are reported.
Reported as:
Number · Percentage of participants
Percentage of Participants Alive (Overall Survival) by Ethnicity
Percentage of participantsProton Therapy (Arm 1)Photon Therapy (Arm 2)
Hispanic or Latino71.4 (43.3 to 99.5)87.5 (68.3 to 100.0)
Not Hispanic or Latino57.5 (43.6 to 71.4)59.3 (44.0 to 74.6)
Unknown or Not Reported0 (NA to NA)100 (NA to NA)
SecondaryPercentage of Participants Alive Without Progression (Progression-free Survival) by HGF Level

Progression is defined as local, regional, or distant progression. Progression-free survival rates are estimated using the Kaplan-Meier method, censoring participants alive without progression at time of last follow-up. HGF will be dichotomized at 2311 pg/mL.

Time frame:
From randomization to progression, death, or last follow-up, whichever occurs first. One- and two-year estimates will be reported.

Results for this outcome have not been posted.

SecondaryChange From Baseline to One Month in PROMIS Fatigue Score by HGF Level

The PROMIS Fatigue Short Form v1.0 8a contains 8 items that assess self-reported fatigue symptoms over the past 7 days. Item responses are summed to obtain a raw score ranging from 8 to 40, which is then converted to a standardized T-score (mean = 50, standard deviation = 10). Higher T-scores indicate greater fatigue. Change from baseline is calculated as the post-baseline T-score minus the baseline T-score, with positive change scores indicating increased fatigue and negative change scores indicating decreased fatigue. HGF will be dichotomized at 2311 pg/mL.

Time frame:
Baseline and one month

Results for this outcome have not been posted.

Adverse events

Collected over From randomization to death or last follow-up. Median follow-up at time of analysis was 20.4 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Proton Therapy (Arm 1)30/57 (52.6%)1/53 (1.9%)53/53 (100%)
Photon Therapy (Arm 2)24/58 (41.4%)5/55 (9.1%)55/55 (100%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventProton Therapy (Arm 1)Photon Therapy (Arm 2)
Hepatic failureHepatobiliary disorders0/532/55
Colonic obstructionGastrointestinal disorders1/530/55
Surgical and medical procedures - Other, specifySurgical and medical procedures1/530/55
AnemiaBlood and lymphatic system disorders0/531/55
Upper gastrointestinal hemorrhageGastrointestinal disorders0/531/55
Infections and infestations - Other, specifyInfections and infestations0/531/55
Blood bilirubin increasedInvestigations0/531/55
HyperglycemiaMetabolism and nutrition disorders0/531/55
SyncopeNervous system disorders0/531/55
ConfusionPsychiatric disorders0/531/55
Most frequent other events
Showing 10 of 97
Most frequent other events
EventProton Therapy (Arm 1)Photon Therapy (Arm 2)
FatigueGeneral disorders and administration site conditions43/5340/55
Platelet count decreasedInvestigations29/5332/55
Lymphocyte count decreasedInvestigations20/5328/55
AnemiaBlood and lymphatic system disorders26/5323/55
NauseaGastrointestinal disorders20/5326/55
ConstipationGastrointestinal disorders24/5317/55
Abdominal painGastrointestinal disorders17/5324/55
Alkaline phosphatase increasedInvestigations20/5322/55
DiarrheaGastrointestinal disorders14/5321/55
White blood cell decreasedInvestigations11/5321/55

Baseline characteristics

Age, Continuous
Age, Continuous(years)Proton Therapy (Arm 1)Photon Therapy (Arm 2)Total
Median73 (66 to 79)71 (65 to 79)72 (65 to 79)
Sex: Female, Male
Sex: Female, Male(Participants)Proton Therapy (Arm 1)Photon Therapy (Arm 2)Total
Female141024
Male434891
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Proton Therapy (Arm 1)Photon Therapy (Arm 2)Total
American Indian or Alaska Native000
Asian213
Native Hawaiian or Other Pacific Islander000
Black or African American145
White504797
More than one race101
Unknown or Not Reported369
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Proton Therapy (Arm 1)Photon Therapy (Arm 2)Total
Hispanic or Latino81321
Not Hispanic or Latino453984
Unknown or Not Reported4610
Zubrod Performance Status
Zubrod Performance Status(Participants)Proton Therapy (Arm 1)Photon Therapy (Arm 2)Total
0262450
1313465
Child Pugh Score
Child Pugh Score(Participants)Proton Therapy (Arm 1)Photon Therapy (Arm 2)Total
A5394180
A6141327
B7448
Alpha-fetoprotein (AFP)
Alpha-fetoprotein (AFP)(mg/mL)Proton Therapy (Arm 1)Photon Therapy (Arm 2)Total
Median6.6 (3.6 to 88.7)12.1 (3.4 to 179.4)9.5 (3.6 to 169.7)
Prior treatment for this cancer
Prior treatment for this cancer(Participants)Proton Therapy (Arm 1)Photon Therapy (Arm 2)Total
No394786
Yes181129

8 further baseline measures are reported on the registry.

08

Study locations

27 sites
09

References and documents

Publications

  • Duda DG. Targeting Tumor Microenvironment in Liver Cancers: Rationale, Current Progress, and Future Perspective. Keio J Med. 2022;71(3):71. doi: 10.2302/kjm.71-004-ABST. PubMed 36155490 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Data sharing details ↗ · grants.nih.gov

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Jan 2026, 95 months.

Results were first posted in Nov 2026, 9 months after primary completion.

Of 86 non-industry phase 3 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 70 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 109. This study's 95 months is above that.

Counting every sponsor, half of 139 studies reached it within 56 months; a quarter within 43 and three quarters within 83.

Completion moved once since we started tracking on Sep 25, 2026: Feb 2027 → Jan 2031, on Nov 3, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2017
First posted
Jun 14, 2017
StartActual
Jan 26, 2018
Primary completionActual
Jan 20, 2026
CompletionEst.
Jan 20, 2031was Feb 2027
Results first posted
Nov 3, 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 3, 2026
Study completion
Feb 4, 2027→Jan 20, 2031
Nov 3, 2026
Enrollment
115→116
Nov 3, 2026
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedHIV positive with CD4 count < 200 cells/microliter; note that patients who are human immunodeficiency virus (HIV) positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 (cluster of differentiation 4)count >= 200 cells/microliter prior to registration; note also that HIV testing is not required for eligibility for this protocol; this exclusion criterion is necessary because the treatments involved in this protocol may be significantly immunosuppressive
Nov 3, 2026
Interventions
Changed Radiation Therapy→Proton Therapy; Radiation Therapy→Photon Therapy. Removed Procedure: Biospecimen Collection·Procedure: Computed Tomography·Laboratory Biomarker Analysis·Procedure: Magnetic Resonance Imaging·Quality-of-Life Assessment. Arms added: Proton Therapy (Arm 1)·Photon Therapy (Arm 2); arms removed: Arm I (proton therapy)·Arm II (photon therapy)
Nov 3, 2026
Primary outcomes
1 added, 2 removed
What changed in the outcomes
  • AddedPercentage of Participants Alive (Overall Survival)Time frame: From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months. One- and two-year estimates are reported.
  • RemovedOverall survival (OS)Time frame: From the date of randomization to the date of death due to any cause assessed up to 48 months after accrual closure
  • RemovedTreatment effectTime frame: Up to 48 months after accrual closure
Nov 3, 2026
Secondary outcomes
7 edited, 5 added, 4 removed
What changed in the outcomes
  • EditedPercentage of Participants Alive Without Progression (Progression-free survival (PFSSurvival)Time frame: From the date of randomization to the date of first PFS failure or last follow-up for patients without a reported PFS event assessed up to 9 years → From randomization to progression, death, or last follow-up, whichever occurs first. Median follow-up time for all patients at time of analysis was 20.4 months. One- and two-year estimates are reported.
  • EditedQuality-adjusted survivalLIfe YearsTime frame: Baseline up to 12 months
  • EditedPercentage of Participants Alive (Overall Survival) by Plasma hepatocyte growth factorHepatocyte Growth Factor (HGF) levelsLevelTime frame: At baseline → From randomization to death or last follow-up. One- and two-year estimates will be reported.
  • AddedPercentage of Participants With Local ProgressionTime frame: From randomization to local progression, death, or last follow-up, whichever occurs first. Median follow-up time for all patients at time of analysis was 20.4 months. One- and two-year estimates are reported.
  • AddedPercentage of Participants With Grade 3+ Treatment-Related Adverse EventsTime frame: From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months.
  • AddedChange From Baseline to One Month in the Patient Reported Outcomes Measurement Information System - Fatigue Short Form version1.0 8a [PROMIS Fatigue Score]Time frame: Baseline and one month
  • AddedPercentage of Participants Alive Without Progression (Progression-free Survival) by HGF LevelTime frame: From randomization to progression, death, or last follow-up, whichever occurs first. One- and two-year estimates will be reported.
  • AddedChange From Baseline to One Month in PROMIS Fatigue Score by HGF LevelTime frame: Baseline and one month
  • RemovedLocal progression (LP)Time frame: From the date of randomization to the date of first LP or date of last follow-up for patients without an LP event reported assessed up to 9 years
  • RemovedIncidence of adverse eventsTime frame: Up to 9 years
  • RemovedFatigueTime frame: Baseline up to 6 months
  • RemovedChange in fatigueTime frame: Baseline up to 1 month
  • Editedother outcomeOverall qualityQuality of lifeLife by Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) versionVersion 4Time frame: Baseline up to 12 months
  • Editedother outcomeTitle: Percentage of Participants Alive (Overall survivalSurvival) by sexSexTime frame: Up to 48 months after accrual closure → From randomization to death or last follow-up. Median follow-up for all patients at time of analysis was 20.4 months. Two-year estimates are reported.
  • Editedother outcomePercentage of Participants Alive (Overall survivalSurvival) by raceRaceTime frame: Up to 48 months after accrual closure → From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months. Two-year estimates are reported.
  • Editedother outcomePercentage of Participants Alive (Overall survivalSurvival) by ethnicityEthnicityTime frame: Up to 48 months after accrual closure → From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months. Two-year estimates are reported.
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Results posted
    Study completion Feb 4, 2027→Jan 20, 2031
    Enrollment 115→116
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedHIV positive with CD4 count < 200 cells/microliter; note that patients who are human immunodeficiency virus (HIV) positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 (cluster of differentiation 4)count >= 200 cells/microliter prior to registration; note also that HIV testing is not required for eligibility for this protocol; this exclusion criterion is necessary because the treatments involved in this protocol may be significantly immunosuppressive
    Primary outcomes 1 added, 2 removed
    What changed in the outcomes
    • AddedPercentage of Participants Alive (Overall Survival)Time frame: From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months. One- and two-year estimates are reported.
    • RemovedOverall survival (OS)Time frame: From the date of randomization to the date of death due to any cause assessed up to 48 months after accrual closure
    • RemovedTreatment effectTime frame: Up to 48 months after accrual closure
    Secondary outcomes 7 edited, 5 added, 4 removed
    What changed in the outcomes
    • EditedPercentage of Participants Alive Without Progression (Progression-free survival (PFSSurvival)Time frame: From the date of randomization to the date of first PFS failure or last follow-up for patients without a reported PFS event assessed up to 9 years → From randomization to progression, death, or last follow-up, whichever occurs first. Median follow-up time for all patients at time of analysis was 20.4 months. One- and two-year estimates are reported.
    • EditedQuality-adjusted survivalLIfe YearsTime frame: Baseline up to 12 months
    • EditedPercentage of Participants Alive (Overall Survival) by Plasma hepatocyte growth factorHepatocyte Growth Factor (HGF) levelsLevelTime frame: At baseline → From randomization to death or last follow-up. One- and two-year estimates will be reported.
    • AddedPercentage of Participants With Local ProgressionTime frame: From randomization to local progression, death, or last follow-up, whichever occurs first. Median follow-up time for all patients at time of analysis was 20.4 months. One- and two-year estimates are reported.
    • AddedPercentage of Participants With Grade 3+ Treatment-Related Adverse EventsTime frame: From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months.
    • AddedChange From Baseline to One Month in the Patient Reported Outcomes Measurement Information System - Fatigue Short Form version1.0 8a [PROMIS Fatigue Score]Time frame: Baseline and one month
    • AddedPercentage of Participants Alive Without Progression (Progression-free Survival) by HGF LevelTime frame: From randomization to progression, death, or last follow-up, whichever occurs first. One- and two-year estimates will be reported.
    • AddedChange From Baseline to One Month in PROMIS Fatigue Score by HGF LevelTime frame: Baseline and one month
    • RemovedLocal progression (LP)Time frame: From the date of randomization to the date of first LP or date of last follow-up for patients without an LP event reported assessed up to 9 years
    • RemovedIncidence of adverse eventsTime frame: Up to 9 years
    • RemovedFatigueTime frame: Baseline up to 6 months
    • RemovedChange in fatigueTime frame: Baseline up to 1 month
    • Editedother outcomeOverall qualityQuality of lifeLife by Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) versionVersion 4Time frame: Baseline up to 12 months
    • Editedother outcomeTitle: Percentage of Participants Alive (Overall survivalSurvival) by sexSexTime frame: Up to 48 months after accrual closure → From randomization to death or last follow-up. Median follow-up for all patients at time of analysis was 20.4 months. Two-year estimates are reported.
    • Editedother outcomePercentage of Participants Alive (Overall survivalSurvival) by raceRaceTime frame: Up to 48 months after accrual closure → From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months. Two-year estimates are reported.
    • Editedother outcomePercentage of Participants Alive (Overall survivalSurvival) by ethnicityEthnicityTime frame: Up to 48 months after accrual closure → From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months. Two-year estimates are reported.
    Interventions Changed Radiation Therapy→Proton Therapy; Radiation Therapy→Photon Therapy. Removed Procedure: Biospecimen Collection·Procedure: Computed Tomography·Laboratory Biomarker Analysis·Procedure: Magnetic Resonance Imaging·Quality-of-Life Assessment. Arms added: Proton Therapy (Arm 1)·Photon Therapy (Arm 2); arms removed: Arm I (proton therapy)·Arm II (photon therapy)
    + 3 other changes: index terms, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03186898
Lead sponsor
NRG Oncology
Responsible party
Sponsor
First posted
Jun 14, 2017
Start date
Jan 26, 2018
Primary completion
Jan 20, 2026
Completion
Jan 20, 2031 (estimated)
Results posted
Nov 3, 2026
Last update
Nov 3, 2026

Study contacts

Theodore S Hong
principal investigator · NRG Oncology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion